Literature DB >> 10834383

Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma.

R Grobholz1, M H Bohrer, M Siegsmund, K P Jünemann, U Bleyl, M Woenckhaus.   

Abstract

Neuroendocrine (NE) differentiated tumor cells are found in almost all prostatic carcinomas. Prostatic carcinomas with a high NE differentiation have a poor prognosis and increased metastatic potential. A relationship between the neovascularisation density in the tumor and the metastatic potential in prostatic carcinoma is well known. NE cells and microvessels were demonstrated immunohistochemically on 102 radical prostatectomy specimens using antibodies against Chromogranin A and CD34. Standard areas (7.9 mm2) of maximal Chromogranin A expression and highest vascularisation were determined and topographically related by light microscopy. Area density of microvessels was evaluated morphometrically. NE tumor cells were present in all prostatic carcinomas studied. High grade prostatic carcinomas expressed significantly more NE tumor cells and exhibited a higher neovascularisation than low grade carcinomas. There was significantly higher neovascularisation in high grade tumors with many, as compared to high grade tumors with few, NE tumor cells. Poorer pathological staging correlated with increased neovascularisation and stronger NE differentiation. A topographical relationship between the area of maximal NE tumor cells and the area of highest neovascularisation was found in 80.4% of all cases. An analysis of variance revealed a large number of NE tumor cells as the only predictor of an increased neovascularisation (p = 0.0006). These observations support the concept that increased neovascularisation is influenced not only by poor pathological grading but also by a high NE differentiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10834383     DOI: 10.1016/S0344-0338(00)80056-4

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  13 in total

1.  [Relevance of the neuroendocrine differentiation in prostatic carcinoma].

Authors:  C G Sauer; L Trojan; R Grobholz
Journal:  Pathologe       Date:  2005-11       Impact factor: 1.011

2.  Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer.

Authors:  Jiaoti Huang; Jorge L Yao; Li Zhang; Patricia A Bourne; Andrew M Quinn; P Anthony di Sant'Agnese; Jay E Reeder
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

3.  Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme.

Authors:  Jochen Tuettenberg; Rainer Grobholz; Tobias Korn; Frederik Wenz; Ralf Erber; Peter Vajkoczy
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-28       Impact factor: 4.553

4.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

5.  Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer.

Authors:  Lutz Trojan; Daniel Thomas; Thomas Knoll; Rainer Grobholz; Peter Alken; Maurice Stephan Michel
Journal:  Urol Res       Date:  2004-05

6.  Oct4A is expressed by a subpopulation of prostate neuroendocrine cells.

Authors:  Paula Sotomayor; Alejandro Godoy; Gary J Smith; Wendy J Huss
Journal:  Prostate       Date:  2009-03-01       Impact factor: 4.104

7.  Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy.

Authors:  Jochen Tuettenberg; Rainer Grobholz; Marcel Seiz; Marc A Brockmann; Frank Lohr; Frederik Wenz; Peter Vajkoczy
Journal:  J Cancer Res Clin Oncol       Date:  2009-03-10       Impact factor: 4.553

8.  Simple models improve the discrimination of prostate cancers from the peripheral gland by T1-weighted dynamic MRI.

Authors:  Fabian Kiessling; Matthias Lichy; Rainer Grobholz; Melanie Heilmann; Nabeel Farhan; Maurice Stephan Michel; Lutz Trojan; Joerg Ederle; Ulrich Abel; Hans-Ulrich Kauczor; Wolfhard Semmler; Stefan Delorme
Journal:  Eur Radiol       Date:  2004-06-30       Impact factor: 5.315

9.  Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens?

Authors:  Heinz-Peter Schlemmer; Jonas Merkle; Rainer Grobholz; Tim Jaeger; Maurice Stephan Michel; Axel Werner; Jan Rabe; Gerhard van Kaick
Journal:  Eur Radiol       Date:  2003-10-03       Impact factor: 5.315

Review 10.  β-Adrenergic Receptor Signaling in Prostate Cancer.

Authors:  Peder Rustøen Braadland; Håkon Ramberg; Helene Hartvedt Grytli; Kristin Austlid Taskén
Journal:  Front Oncol       Date:  2015-01-12       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.